Finance

Lists
Q3 2026 earnings • released • EPS beat +3.23% • Revenue beat +0.61%
See results
HYPE3:BVMF
Hypera SA
R$21.27
0.00%
(0.00) 1D
Oct 30, 5:05:38 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for HYPE3...
Open
R$21.27
High
R$21.67
Low
R$20.95
Mkt. cap
14.97B
Avg. vol.
5.29M
Volume
7.29M
Dividend
4.51%
Quarterly dividend
R$0.24
Ex-dividend date
Feb 9, 2026
P/E ratio
7.92
52-wk high
R$30.00
52-wk low
R$19.41
EPS
R$2.69
Shares outstanding
704.01M
No. of employees
11K
Open
R$21.27
High
R$21.67
Low
R$20.95
Mkt. cap
14.97B
Avg. vol.
5.29M
Volume
7.29M
Dividend
4.51%
Quarterly dividend
R$0.24
Ex-dividend date
Feb 9, 2026
P/E ratio
7.92
52-wk high
R$30.00
52-wk low
R$19.41
EPS
R$2.69
Shares outstanding
704.01M
No. of employees
11K
News stories
From web sources and news partners
Profile
Hypera Pharma is a Brazilian multinational pharmaceutical company and is the largest Brazilian pharmaceutical company by market capitalization. Headquartered in São Paulo, its business include pharmaceuticals, consumer healthcare and cosmetics products, and biotechnology products. Wikipedia
About Hypera SA
CEO-
Employees10.6K
Founded2001
HeadquartersItaim Bibi, São Paulo, Brazil
SectorPharmaceutical industry
Websitehypera.com.br
Last report
Oct 28, 2026
Fiscal period
Q3 2026
R$0.75 / R$0.73
+3.23%beat
Revenue / Est. (BRL)
2.44B / 2.42B
+0.61%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in BRL
Loading Previous Earnings...
Revenue
Net income
All values in BRL
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
2.24B
2.02B
2.34B
2.44B
Cost of goods sold
858.94M
807.22M
892.99M
942.08M
Cost of revenue
858.94M
807.22M
892.99M
942.08M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
728.46M
703.28M
780.69M
780.27M
Operating expense
728.74M
701.06M
773.84M
793.15M
Total operating expenses
1.59B
1.51B
1.67B
1.74B
Operating income
649.38M
509.50M
669.87M
700.59M
Other non operating income
-27.28M
-8.73M
-30.17M
-
EBT including unusual items
439.21M
276.14M
492.29M
558.27M
EBT excluding unusual items
438.30M
279.75M
488.66M
558.27M
Income tax expense
-10.46M
-69.54M
2.28M
31.31M
Effective tax rate
-2.38%
-25.18%
0.46%
5.61%
Other operating expenses
283.00K
-2.21M
-6.84M
12.88M
Net income
450.99M
347.38M
490.24M
523.15M
Net profit margin
20.16%
17.22%
20.98%
21.48%
Earnings per share
0.71
0.55
0.70
0.75
Interest and investment income
68.87M
64.66M
63.02M
69.02M
Interest expense
-268.84M
-282.34M
-209.57M
-217.27M
Net interest expenses
-199.97M
-217.68M
-146.55M
-148.25M
Depreciation and amortization charges
-
-
-
-
EBITDA
702.34M
562.68M
755.79M
776.33M
Gain or loss from assets sale
-253.00K
-3.20M
-698.00K
-117.00K
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps